---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-24-000019"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:47:46.662218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS

## Summary
- Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.
- R&D expense $13.0M in Q1 (up from $8.1M prior Q) due to trial initiations; G&A $6.8M.
- Positive FDA and EMA feedback for Phase 3 VELA program in HS; topline data expected mid-2025.
- ARGO Phase 2 in PsA: up to 52% ACR50+PASI100 and 61% MDA at week 24, suggesting best-in-class profile.
- Plans to initiate four additional trials in PPP, juvenile HS, seronegative spondyloarthritis in 2H 2024.

## SEC filing metadata
- accession: 0001821586-24-000019
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/0001821586-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/mnlk-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-24-000019
- JSON: https://secwatch.observer/filing/0001821586-24-000019.json
- Plain text: https://secwatch.observer/filing/0001821586-24-000019.txt

## Key facts
- Earnings Releases
  MoonLake Immunotherapeutics reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000019/0001821586-24-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.